China's Sciwind Pursues US Weight-Loss Drug License: CEO Talks Ongoing

Sciwind, a Chinese biotech firm, is in talks to license a weight-loss drug in the US. The CEO has not disclosed the name of the drug, but mentioned that it has shown promising results in clinical trials. The potential deal would be a significant milestone for Sciwind, which has been expanding its presence globally.

Sciwind, a Chinese biotech firm, is in advanced discussions to license a weight-loss drug in the United States. The CEO, while remaining tight-lipped about the specific drug's name, has highlighted its promising results in clinical trials. This potential deal could mark a significant milestone for Sciwind, which has been expanding its global presence [1].

The weight loss drug market remains a highly promising sector, with analysts predicting that it could reach a market size of around $100 billion by 2030 [2]. This growth is driven by the increasing prevalence of obesity worldwide, with an estimated one-fourth of the global population expected to be obese by 2035 [3].

Sciwind's potential entry into the US market follows the recent underperformance of Eli Lilly's Zepbound, which raised concerns about market demand. However, Novo Nordisk's strong sales performance with Wegovy has reassured investors [1]. This suggests that despite the challenges faced by some players, the market remains robust.

The deal would not only expand Sciwind's footprint but also add to the growing list of pharmaceutical companies investing in weight loss drugs. Other notable players include Novo Nordisk, which is developing CagriSema, a combination therapy that combines semaglutide with a prandial insulin analogue [1].

References:
[1] https://www.moomoo.com/news/post/57430158/record-tr4cking-news-default
[2] https://www.moomoo.com/news/post/57430158/record-tr4cking-news-default
[3] https://www.moomoo.com/news/post/57430158/record-tr4cking-news-default